These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19892543)

  • 1. Safety of biologics, lessons learnt from TGN1412.
    Stebbings R; Poole S; Thorpe R
    Curr Opin Biotechnol; 2009 Dec; 20(6):673-7. PubMed ID: 19892543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.
    Stebbings R; Findlay L; Edwards C; Eastwood D; Bird C; North D; Mistry Y; Dilger P; Liefooghe E; Cludts I; Fox B; Tarrant G; Robinson J; Meager T; Dolman C; Thorpe SJ; Bristow A; Wadhwa M; Thorpe R; Poole S
    J Immunol; 2007 Sep; 179(5):3325-31. PubMed ID: 17709549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. After TGN1412: recent developments in cytokine release assays.
    Stebbings R; Eastwood D; Poole S; Thorpe R
    J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
    Eastwood D; Findlay L; Poole S; Bird C; Wadhwa M; Moore M; Burns C; Thorpe R; Stebbings R
    Br J Pharmacol; 2010 Oct; 161(3):512-26. PubMed ID: 20880392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials.
    Mehrishi JN; Szabó M; Bakács T
    Vaccine; 2007 May; 25(18):3517-23. PubMed ID: 17397974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of phase I clinical trials with monoclonal antibodies in Germany--the regulatory requirements viewed in the aftermath of the TGN1412 disaster.
    Liedert B; Bassus S; Schneider CK; Kalinke U; Löwer J
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):1-9. PubMed ID: 17256444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunostimulatory antibodies: challenging the drug testing paradigm.
    Bhogal N; Combes R
    Toxicol In Vitro; 2007 Oct; 21(7):1227-32. PubMed ID: 17434714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies.
    Dhir V; Fort M; Mahmood A; Higbee R; Warren W; Narayanan P; Wittman V
    J Immunotoxicol; 2012; 9(1):34-42. PubMed ID: 22074378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?
    Tranter E; Peters G; Boyce M; Warrington S
    Br J Clin Pharmacol; 2013 Aug; 76(2):164-72. PubMed ID: 23438102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
    Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
    J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New administration routes for immunotherapy].
    Martorell Aragonés A
    Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hazard identification and risk assessment for biologics targeting the immune system.
    Weir AB
    J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
    Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
    J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
    Messer K; Natarajan L; Ball ED; Lane TA
    Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [After the TGN1412 incident. Principles for assessment of first-in-man trials with monoclonal antibodies by the Paul Ehrlich Institute].
    Schneider CK; Kalinke U
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Oct; 50(10):1213-20. PubMed ID: 17924065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.